JP2023525320A5 - - Google Patents
Info
- Publication number
- JP2023525320A5 JP2023525320A5 JP2022568560A JP2022568560A JP2023525320A5 JP 2023525320 A5 JP2023525320 A5 JP 2023525320A5 JP 2022568560 A JP2022568560 A JP 2022568560A JP 2022568560 A JP2022568560 A JP 2022568560A JP 2023525320 A5 JP2023525320 A5 JP 2023525320A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- use according
- drug conjugate
- aminobenzyloxycarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023495P | 2020-05-12 | 2020-05-12 | |
| US63/023,495 | 2020-05-12 | ||
| US202163180795P | 2021-04-28 | 2021-04-28 | |
| US63/180,795 | 2021-04-28 | ||
| PCT/US2021/031598 WO2021231309A1 (en) | 2020-05-12 | 2021-05-10 | Methods for the use of a b7-h3 antibody-drug conjugate alone or in combination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023525320A JP2023525320A (ja) | 2023-06-15 |
| JP2023525320A5 true JP2023525320A5 (enExample) | 2024-05-20 |
Family
ID=78524901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568560A Pending JP2023525320A (ja) | 2020-05-12 | 2021-05-10 | Ｂ７‐ｈ３抗体薬物複合体の単独使用又は併用のための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230226206A1 (enExample) |
| EP (1) | EP4149549A4 (enExample) |
| JP (1) | JP2023525320A (enExample) |
| KR (1) | KR20230009397A (enExample) |
| CN (1) | CN115484982A (enExample) |
| AU (1) | AU2021273467A1 (enExample) |
| BR (1) | BR112022022900A2 (enExample) |
| CA (1) | CA3181535A1 (enExample) |
| IL (1) | IL298105A (enExample) |
| MX (1) | MX2022014068A (enExample) |
| TW (1) | TW202207991A (enExample) |
| WO (1) | WO2021231309A1 (enExample) |
| ZA (1) | ZA202211455B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240058463A1 (en) * | 2020-12-18 | 2024-02-22 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof |
| KR20260060334A (ko) * | 2023-08-25 | 2026-05-04 | 마크로제닉스, 인크. | B7-h3 항체-약물 접합체 |
| TW202600174A (zh) * | 2024-02-07 | 2026-01-01 | 大陸商上海翰森生物醫藥科技有限公司 | 抗體藥物偶聯物和抗ｅｇｆｒ抗體的聯合應用 |
| WO2026057014A1 (zh) * | 2024-09-13 | 2026-03-19 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体及其医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2542256T3 (da) * | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN109069633A (zh) * | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| CN110305213B (zh) * | 2018-11-09 | 2023-03-10 | 泰州复旦张江药业有限公司 | 一种抗b7-h3抗体及其制备方法、其偶联物和应用 |
| KR20210063070A (ko) * | 2019-11-22 | 2021-06-01 | 주식회사 레고켐 바이오사이언스 | 항-b7-h3 항체를 포함하는 항체-약물 접합체 및 이의 용도 |
-
2021
- 2021-05-10 AU AU2021273467A patent/AU2021273467A1/en active Pending
- 2021-05-10 CN CN202180031984.8A patent/CN115484982A/zh active Pending
- 2021-05-10 KR KR1020227040047A patent/KR20230009397A/ko active Pending
- 2021-05-10 WO PCT/US2021/031598 patent/WO2021231309A1/en not_active Ceased
- 2021-05-10 JP JP2022568560A patent/JP2023525320A/ja active Pending
- 2021-05-10 MX MX2022014068A patent/MX2022014068A/es unknown
- 2021-05-10 EP EP21805196.9A patent/EP4149549A4/en active Pending
- 2021-05-10 IL IL298105A patent/IL298105A/en unknown
- 2021-05-10 BR BR112022022900A patent/BR112022022900A2/pt unknown
- 2021-05-10 CA CA3181535A patent/CA3181535A1/en active Pending
- 2021-05-10 US US17/998,455 patent/US20230226206A1/en not_active Abandoned
- 2021-05-11 TW TW110117006A patent/TW202207991A/zh unknown
-
2022
- 2022-10-19 ZA ZA2022/11455A patent/ZA202211455B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11136633B2 (en) | Site-specific conjugation of linker drugs to antibodies and resulting ADCS | |
| ES2889398T3 (es) | Anticuerpos anti-5T4 y conjugados de anticuerpo-fármaco | |
| WO2021142043A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| JP2018509182A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| AU2016308365A1 (en) | Anti-DLL3 antibody drug conjugates and methods of use | |
| JP2021528471A5 (enExample) | ||
| JP2023536086A5 (enExample) | ||
| JP2024536881A5 (enExample) | ||
| JP2020532523A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| WO2024153127A1 (zh) | 抗体偶联药物及其用途 | |
| JP2020532543A (ja) | 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用 | |
| TW202508637A (zh) | 修飾的抗體、其抗體片段和抗體藥物偶聯物 | |
| JP2025540920A (ja) | 二重特異性抗体化合物 | |
| JPWO2021251459A5 (enExample) | ||
| JP2025525410A (ja) | 癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ | |
| JP2024515266A5 (enExample) | ||
| JP2025506142A5 (enExample) | ||
| WO2025113644A1 (zh) | Pd-l1结合分子与蛋白-药物偶联物的组合及其用途 | |
| KR20250048287A (ko) | 새로운 티올 환원제, 제조 방법 및 용도 | |
| CN118681035A (zh) | 一类配体药物偶联物及其制备方法和用途 | |
| JP2024540536A5 (enExample) | ||
| JPWO2022019259A5 (enExample) | ||
| WO2025151684A1 (en) | Antibody-auristatin drug conjugates and methods of making and using thereof | |
| HK40118815A (en) | Antibody-drug conjugate and use thereof |